Newly Diagnosed Glioblastoma

Oncology·MeSH: Brain Neoplasms

Prevalence

3.2 / 100K

Incidence

3.2 / 100K/yr

4 drugs in development·3 companies·4 clinical trials

Drug Pipeline by Phase

Phase 2(1)
DrugCompany
inb-400IN8BIO, INC. (INAB)

Compare drugs

ict-107 vs inb-400ict-107 vs immunizationict-107 vs inb-200

Frequently asked questions

How many drugs are in development for Newly Diagnosed Glioblastoma?

BioSniper tracks 4 drugs in development for Newly Diagnosed Glioblastoma across 3 companies.

How many clinical trials target Newly Diagnosed Glioblastoma?

There are 4 clinical trials targeting Newly Diagnosed Glioblastoma tracked by BioSniper.

What is the prevalence of Newly Diagnosed Glioblastoma?

The estimated prevalence of Newly Diagnosed Glioblastoma is approximately 3.2 per 100,000 population.

Deep-dive into Newly Diagnosed Glioblastoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Newly Diagnosed Glioblastoma — Drugs in Development & Clinical Trials | BioSniper